NCI-2020-13347

P-RAD A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

 This research study is designed to study a new treatment for triple-negative breast cancer (TNBC). The trial is looking at the effectiveness of a combination of preoperative chemotherapy, pembrolizumab, and different radiation doses. Pembrolizumab is a drug that helps the immune system fight cancer cells. The goal of the trial is to see if adding pembrolizumab and different radiation doses to chemotherapy is safe and effective for women with TNBC.

Triple-negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04443348

NCI-2020-13347

Clinical Trial Site: Einstein

To see all available clinical trials click here.